FDA Issues Alert On Rituxan; Plans To Strengthen Warnings On Risk Of PML
This article was originally published in The Pink Sheet Daily
Executive Summary
Alert follows death of two patients treated with rituximab for an off-label indication.
You may also be interested in...
Rituxan Market Expansion In Rheumatoid Arthritis Patients Sidelined By PML Risk
FDA issues a "complete response" to Genentech/Biogen Idec for sBLA for Rituxan in earlier-stage rheumatoid arthritis.
Rituxan Market Expansion In Rheumatoid Arthritis Patients Sidelined By PML Risk
FDA issues a "complete response" to Genentech/Biogen Idec for sBLA for Rituxan in earlier-stage rheumatoid arthritis.
Genentech Posts Solid Second Quarter
EPS misses consensus, but sales of most products modestly estimates.